BCL2 and neoplasm: In addition to genomic abnormalities, soluble factors present in the tumor microenvironment, including CD40L and certain cytokines (e.g., IGF-1, BAFF, IL-6, IL-10), appear to be able to reduce the dependence of certain B-cell malignancies on BCL2 by upregulating one or more alternative pro-survival proteins [96,100,101,102].